Metoprolol Succinate and Weight Gain
Yes, metoprolol succinate can cause weight gain, though the effect is modest (approximately 1.2 kg) and primarily occurs during the first few months of treatment. However, this weight gain is not inevitable and varies significantly among individuals, with the most pronounced effects seen in patients with obesity and diabetes.
Evidence for Weight Gain
Multiple clinical practice guidelines and research studies confirm that β-blockers as a class are associated with weight gain 1, 2, 1. A meta-analysis of randomized controlled hypertension trials lasting at least 6 months showed a median weight difference of 1.2 kg between β-blocker groups and control groups 2.
Specifically for metoprolol, the GEMINI trial (n=1,106 patients with type 2 diabetes and hypertension) demonstrated that metoprolol tartrate-treated patients experienced a statistically significant mean weight gain of 1.19 kg over 5 months (P <0.001), while carvedilol-treated patients did not gain weight 3. The weight gain was most pronounced in obese patients:
- Patients with BMI >30 kg/m²: 0.90 kg greater weight gain with metoprolol vs. carvedilol (P = 0.002)
- Patients with BMI >40 kg/m²: 1.84 kg greater weight gain with metoprolol vs. carvedilol (P = 0.001) 3
Mechanism of Weight Gain
The weight gain associated with β-blockers occurs through several mechanisms 1:
- Decreased metabolic rate: β-blockers can reduce resting energy expenditure by approximately 10%, translating to 50-100 kcal/day reduction 4, 5
- Reduced facultative thermogenesis: Decreased thermogenic response to meals, cold exposure, and stress 5
- Potential adverse effects on insulin sensitivity: May contribute to metabolic changes 1
Importantly, the weight gain appears to occur primarily during the first few months of treatment, with no further progressive weight gain thereafter 6.
Clinical Implications and Alternatives
When β-Blockers Are Required
If β-blockers are necessary (e.g., for coronary artery disease, heart failure, or arrhythmias), selective β-blockers with vasodilating properties such as carvedilol and nebivolol are recommended over metoprolol 1, 2, 1, 2, 1. These agents:
- Have less potential for weight gain
- Minimally affect lipid and glucose metabolism
- Maintain cardiovascular benefits
For Hypertension Management
For first-line hypertension treatment in patients with obesity concerns, ACE inhibitors, ARBs, and calcium channel blockers are preferred over β-blockers 2. These alternatives:
- Are weight-neutral
- Do not adversely affect insulin sensitivity
- Provide renal protection in diabetes
- Are particularly appropriate given that angiotensin is overexpressed in obesity 2
Important Caveats
Individual variation: Not all patients on metoprolol will experience weight gain; the effect varies considerably among individuals 3
Risk stratification: Patients with pre-existing obesity and diabetes are at highest risk for weight gain and should be counseled accordingly 3
No correlation with other metabolic parameters: In the GEMINI trial, weight changes showed no significant correlation with changes in HbA1c, HOMA-IR, or blood pressure 3
Clinical context matters: The modest weight gain must be weighed against the cardiovascular benefits of β-blockade in appropriate clinical scenarios (post-MI, heart failure, etc.) 7, 8
Monitoring: Patients should be advised to monitor weight and report significant changes, particularly those with pre-existing obesity or metabolic syndrome 9